Valeritas’ V-Go Wearable Insulin Delivery Device Results In Significant Reductions In A1C, Insulin Requirements And Cost Reductions In Patients With Diabetes
Data presented at the ISPOR 22nd Annual International Meeting, May 20-24, 2017
“Both studies support that significant cost savings can be associated with improved clinical outcomes with the V-Go Wearable Insulin Delivery device for patients with diabetes,” said
Abstract #71796 / Poster #PMD31: Evaluation of Real World Clinical and Pharmacy Budget Outcomes when Switching to a Wearable Insulin Delivery Device for
This retrospective analysis was based on an electronic medical records database queried to identify patients exceeding glycemic targets (A1C greater than 7%) who switched to V-Go insulin delivery device from multiple daily injections (MDI). The evaluated variables were extracted at baseline and included up to 3 follow up visits, post V-Go initiation. Clinical and pharmacy budget comparisons to baseline were evaluated in patients with greater than or equal to five months of continuous V-Go use during the observation period. The impact to pharmacy budget per patient was derived by applying average unit pricing from market leaders for both basal and prandial insulins as well as pricing for insulin delivery via pen needles/syringes and V-Go for prescribed insulin therapy. All costs were based on a normalized 30-day supply and published wholesale acquisition costs (WAC) in
Abstract #71569 / Poster #PMD39: A Prospective Pragmatic Clinical Trial to Compare the Real-World Use of a Wearable Insulin Delivery Device to Standard Treatment Optimization in Type 2 Diabetes Patients with Poor Glycemic Control using Multiple Daily Insulin Injections
This study analyzed a cluster randomized prospective pragmatic clinical trial (PCT) in a community-based practice setting, where study sites rather than individual patients, were randomized to initiate V-Go and stop other insulin therapy or to optimize and add other diabetes treatments. Patients with type 2 diabetes taking insulin were enrolled in both groups and treated according to routine practice for up to four months. All treatments and medications were obtained by usual care utilizing patient health insurance. The analysis population included 52 sites in
About
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in
Forward Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the
Investor Contacts:Nick Laudico /Robert Flamm , Ph.D.The Ruth Group (646)536-7030 / 7017 IR@valeritas.com OrThe Del Mar Consulting Group, Inc. Robert B. Prag , President 858-794-9500 bprag@delmarconsulting.com Media Contact:Kirsten Thomas The Ruth Group (508)280-6592 PR@valeritas.com